Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Wexford Capital LP

Wexford Capital LP reduced its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 16.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,872 shares of the company's stock after selling 16,351 shares during the quarter. Wexford Capital LP owned approximately 0.14% of Structure Therapeutics worth $2,220,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after acquiring an additional 553 shares during the period. Virtus ETF Advisers LLC lifted its stake in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares during the period. Assetmark Inc. lifted its stake in Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after acquiring an additional 953 shares during the period. Tower Research Capital LLC TRC lifted its stake in Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after acquiring an additional 3,549 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Structure Therapeutics in the fourth quarter worth about $113,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Down 0.4%

Shares of GPCR traded down $0.10 during midday trading on Friday, reaching $24.55. The company had a trading volume of 267,802 shares, compared to its average volume of 930,562. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The stock has a market cap of $1.41 billion, a PE ratio of -33.18 and a beta of -1.69. The firm has a 50 day simple moving average of $21.53 and a 200-day simple moving average of $26.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GPCR. Citigroup started coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. HC Wainwright decreased their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Finally, William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $79.86.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.